Lv42
480 积分 2025-04-22 加入
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
5小时前
已完结
Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis
14小时前
已完结
Combination of anlotinib with immunotherapy enhanced both anti-angiogenesis and immune response in high-grade serous ovarian cancer
14小时前
已完结
Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
14小时前
已完结
Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma
18小时前
已完结
Targeting CXCL8 signaling sensitizes HNSCC to anlotinib by reducing tumor-associated macrophage-derived CLU
22小时前
已完结
Promoting tumor cell secretion of IL18 to induce reprogramming of tumor-associated macrophages – The novel anticancer mechanism of anlotinib in ovarian cancer
11天前
已完结
Host stimulator of interferon genes is essential for the efficacy of anti‐programmed cell death protein 1 inhibitors in non‐small cell lung cancer
11天前
已完结
Targeting CXCL8 signaling sensitizes HNSCC to anlotinib by reducing tumor-associated macrophage-derived CLU
12天前
已完结
Targeting macrophages: therapeutic approaches in cancer
13天前
已完结
皖公网安备34019202002308
